Bluejay Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Bluejay Diagnostics şirketinin toplam hissedar öz sermayesi $8.6M ve toplam borcu $147.4K olup, bu da borç-öz sermaye oranını 1.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $10.9M ve $2.2M dir.

Anahtar bilgiler

1.7%

Borç/özkaynak oranı

US$147.44k

Borç

Faiz karşılama oranı	n/a
Nakit	US$8.06m
Eşitlik	US$8.64m
Toplam yükümlülükler	US$2.22m
Toplam varlıklar	US$10.86m

Son finansal sağlık güncellemeleri

Is Bluejay Diagnostics (NASDAQ:BJDX) In A Good Position To Invest In Growth?

Jul 24

We Think Bluejay Diagnostics (NASDAQ:BJDX) Can Afford To Drive Business Growth

Jun 16

Recent updates

Is Bluejay Diagnostics (NASDAQ:BJDX) In A Good Position To Invest In Growth?

Jul 24

We Think Bluejay Diagnostics (NASDAQ:BJDX) Can Afford To Drive Business Growth

Jun 16

Bluejay Diagnostics (NASDAQ:BJDX) Is In A Good Position To Deliver On Growth Plans

Mar 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BJDX 'nin kısa vadeli varlıkları ( $9.0M ) kısa vadeli yükümlülüklerini ( $2.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: BJDX şirketinin kısa vadeli varlıkları ( $9.0M ) uzun vadeli yükümlülüklerini ( $161.3K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BJDX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: BJDX şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: BJDX şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: BJDX un, serbest nakit akışı her yıl % 41.4 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Bluejay Diagnostics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq’s Listing Qualifications Staff Extends the Time Period for Bluejay Diagnostics to Regain Compliance with the Minimum Bid Requirement Until February 24, 2025

Bluejay Diagnostics Receives Notification Letter from The Nasdaq Stock Market Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Is Bluejay Diagnostics (NASDAQ:BJDX) In A Good Position To Invest In Growth?

Bluejay Diagnostics Receives Notification Letter from the Nasdaq Listing Qualifications Staff of the NASDAQ

We Think Bluejay Diagnostics (NASDAQ:BJDX) Can Afford To Drive Business Growth

Recent updates

Nasdaq’s Listing Qualifications Staff Extends the Time Period for Bluejay Diagnostics to Regain Compliance with the Minimum Bid Requirement Until February 24, 2025

Bluejay Diagnostics, Inc. has completed a Composite Units Offering in the amount of $8.75 million.

New major risk - Share price stability

New major risk - Financial position

New major risk - Revenue and earnings growth

Bluejay Diagnostics, Inc., Annual General Meeting, May 14, 2024

Bluejay Diagnostics Receives Notification Letter from The Nasdaq Stock Market Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients

Bluejay Diagnostics, Inc. has filed a Follow-on Equity Offering.

New major risk - Financial position

New minor risk - Shareholder dilution

Bluejay Diagnostics, Inc. announced that it has received $1.59084 million in funding

Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Is Bluejay Diagnostics (NASDAQ:BJDX) In A Good Position To Invest In Growth?

Bluejay Diagnostics, Inc. Updates Symphony IL-6 Regulatory Strategy

Bluejay Diagnostics, Inc., Annual General Meeting, Jun 14, 2023

Bluejay Diagnostics Receives Notification Letter from the Nasdaq Listing Qualifications Staff of the NASDAQ

Bluejay Diagnostics Presents Positive Clinical Results for its Symphony IL-6 Test at AACC 2022

Bluejay Diagnostics, Inc. Completes Planned Clinical Studies for Symphony IL-6 Test

We Think Bluejay Diagnostics (NASDAQ:BJDX) Can Afford To Drive Business Growth

Bluejay Reports FDA Agrees to Consider Its Plan to Pursue A De Novo Regulatory Pathway for the Symphony II-6 Test

Bluejay Diagnostics, Inc., Annual General Meeting, Jun 09, 2022

Bluejay Diagnostics (NASDAQ:BJDX) Is In A Good Position To Deliver On Growth Plans

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin